

**Dardiotis Efthimios, MD, PhD**

Professor, Department of Neurology, Faculty of Medicine, University of Thessaly Head of Department of Neurology, General University Hospital of Larissa, Greece

**Contact details**

Department of Neurology, General University Hospital of Larissa, Viopolis, GR 41110, Larissa, GREECE  
TEL: +302413501137, mob: +306974224279. FAX: +302413501010, E-mail: [edar@med.uth.gr](mailto:edar@med.uth.gr), [ebdsdar@gmail.com](mailto:ebdsdar@gmail.com)

**Education and Training**

1997	Graduation (BA degree) from Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, Medical Licence Number: 92691
2008	Specialization in clinical Neurology at the Department of Neurology, General University Hospital of Larissa, Greece
2008	PhD in Neurology, Faculty of Medicine, University of Thessaly, Greece
2007-2009	Post-doctoral fellow, Cyprus Institute of Neurology and Genetics (CING), Cyprus
2011	MA in Health Administration, Hellenic Open University, Greece
2010-2013	Lecturer in Neurology, University of Thessaly, Larissa
2015	MA in Research Methodology in Biomedicine, Biostatistics and Clinical Bioinformatics, University of Thessaly, Greece
2013-2019	Assistant Professor, Department of Neurology, Faculty of Medicine, University of Thessaly
2018-2023	Head of Department of Neurology, General University Hospital of Larissa, Greece
2023/10/25	Professor, Department of Neurology, Faculty of Medicine, University of Thessaly Head of Department of Neurology, General University Hospital of Larissa, Greece

**Professional Activities**

1. Head of the multi-disciplinary Multiple Sclerosis centre of the Department of Neurology, General University Hospital of Larissa, Greece
2. Member of the Greek Neurological Society
3. Member of the European Neurological Society
4. Member of the Hellenic Society of Immunology

**Major scientific interests**

1. Genetic epidemiology of Multiple Sclerosis (member of International Multiple Sclerosis Genetics Consortium, IMSGC)
2. Genetic epidemiology of Amyotrophic Lateral Sclerosis (member of NYGC ALS Consortium)
3. Epidemiology of Guillain-Barré Syndrome (national coordinator of International Guillain-Barré Syndrome Outcome Study, IGOS)
4. Epidemiology of Alzheimer's disease (member of HELIAD study)
5. Genetic basis and epidemiology of Parkinson's Disease (member of GEO-PD, LONG-PD study) (member of)
6. The chemotherapy-induced peripheral neuropathy outcome measures standardization study (member of International CIPN study)
7. Genetic basis and epidemiology of myopathies (Collaboration with Prof Kyriakides, Cyprus, University of Nicosia Medical School)
8. Role of rTMS in cognitive rehabilitation (collaboration with Prof Tsapkini, Department of Neurology, Johns Hopkins School of Medicine, Department of Cognitive Science, Baltimore, USA)

**Participation in Phase II/ III Clinical trials:**

1. Bousser et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. *Lancet*. 2011 Jun 11;377(9782):2013-22. (site PI. Prof Papadimitriou, Position: Investigator)

2. Kappos et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet*. 2018 Mar 31;391(10127):1263-1273. (Potition: site P.I. Dardiotis E)
3. Diener et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. *N Engl J Med*. 2019 May 16;380(20):1906-1917. (Potition: site P.I. Dardiotis E)
4. Moves-PD: Phase 2 trial to study the safety and efficacy of GZ/SAR402671 for treating Parkinson's disease (PD) in patients carrying a mutation in the GBA gene. ACT14820/MOVES-PD. (Potition: site PI: Dardiotis E)
5. A Study of Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis, *ClinicalTrials.gov* Identifier: NCT02975349. (Potition: site PI: Dardiotis E)
6. An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension. 105MS306, 2018-003008-38. (Potition: site PI: Dardiotis E)
7. Medicinova-MN-166-ALS-2301. A Phase 2B/3, Multi-center, randomised, double-blind, placebo-controlled, 12 months clinical trial to evaluate the efficacy and safety of MN-166 (Ibudilast) followed by an open-label extension in subjects with amyotrophic lateral sclerosis (Potition: site PI: Dardiotis E)

## Funding

1. Title of research project: "Mediterranean Diet and Alzheimer's disease in the Mediterranean Region". Sponsor: Alzheimer's Association, USA. Award Number: IIRG-09-133014. PI: N. Scarmeas, Columbia University, New York, USA. Duration: 2010-2012. (Position: site investigator)
2. Title of research project: "A study of modifier genes on disease severity in Multiple Sclerosis". PI: T. Kyriakides, Cyprus Institute of Neurology & Genetics (CING). Sponsor: European Regional Development Fund under the Framework programme for Research, Technological Development and Innovation. Duration: 2009-2010. (Position: Site investigator)
3. Title of research project: "Heterogeneity of autoimmune diseases: understanding of disease-specific and patient-specific mechanisms". PI: S. Tzartos. Sponsor: THALES. Duration: 2012-2015. (Position: Site investigator)
4. Title of research project: "Diet and Alzheimer's disease in the Mediterranean (MeDi and AD)". PI: N. Skarmeas. Sponsor: Framework (NSRF) - Research Funding Program ARISTEIA (Excellence). Duration: 2012-2015. (Position: Site Investigator)
5. Title of research project: "Helicobacter pylori Bregs modulation in MS", Hellenic Academy of Neuroimmunology (Hellani), November 2015, 10.000 €, (Position: Principal Investigator)
6. Title of research project: "Neurogenetics-Neuroimmunogy". Research Committee, University of Thessaly, 100.000 € (Position: Principal Investigator).
7. Day Center for the Support of Alzheimer's disease patients in Larissa, Thessaly administrative division, March 2019, 416.562 € (Position: Principal Investigator).
8. Greek Diaspora Fellowship Program (GDFF), Nov 2019. 20.000 \$, (Position: Principal Investigator).

## Publications: Over 350 articles in peer-reviewed journals

### Selected Publications

1. IMSGC. Multiple Sclerosis Genomic Map Implicates Peripheral Immune Cells and Microglia in Susceptibility. *Science*. 2019 Sep 27;365(6460).
2. IMSGC. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. *Cell*. 2019 Jun 27;178(1):262
3. IMSGC. A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. *Nat Commun*. 2019 May 20;10(1):2236.
4. Diener et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. *N Engl J Med*. 2019 May 16;380(20):1906-1917.
5. Dardiotis et al. Gene variants of adhesion molecules predispose to MS: A case-control study. *Neurol Genet*. 2019 Jan 16;5(1):e304.
6. Doets et al. Regional variation of Guillain-Barré syndrome. *Brain*. 2018 Oct 1;141(10):2866-2877

7. Conlon et al. Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism. *Elife*. 2018 Jul 13;7. pii: e37754. doi: 10.7554/eLife.37754.
8. Slot et al. Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. *Alzheimers Dement*. 2018 Dec 13. pii: S1552-5260(18)33563-5.
9. Dardiotis et al. Genetic polymorphisms in amyotrophic lateral sclerosis: Evidence for implication in detoxification pathways of environmental toxicants. *Environ Int*. 2018 Jul;116:122-135
10. Nicolas et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron*. 2018 Mar 21;97(6):1268-1283.e6.
11. Dardiotis et al. Gene variants of adhesion molecules act as modifiers of disease severity in MS. *Neurol Neuroimmunol Neuroinflamm*. 2017 Apr 24;4(4):e350.
12. Lipnicki et al. Age-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study. *PLoS Med*. 2017 Mar 21;14(3):e1002261.
13. Dardiotis et al. A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature. *Neurobiol Aging*. 2017 May;53:194.e13-194.e22.
14. Dardiotis et al. Paraneoplastic neuromyotonia. *N Engl J Med*. 2015 Apr 30;372(18):e24.
15. Dardiotis et al. The Hellenic Longitudinal Investigation of Aging and Diet (HELIAD): Rationale, Study Design, and Cohort Description. *Neuroepidemiology*. 2014;43(1):9-14.
16. Nalls et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet*. 2014 Sep;46(9):989-93
17. Dardiotis et al. The interplay between environmental and genetic factors in Parkinson's disease susceptibility: the evidence for pesticides. *Toxicology*. 2013 May 10;307:17-23
18. Dardiotis E, Patramani G, Ralli S, Hadjigeorgiou GM. Isolated bilateral trigeminal nerve palsy. *Neurology*. 2011;76(24):e115
19. Ross et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. *Lancet Neurol*. 2011;10(10):898-908.
20. Dardiotis et al. Genetic Association Studies in Patients with Traumatic Brain Injury. *Neurosurgical focus*. 2010;28(1):E9.

